These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32720933)

  • 1. Implications of the Mechanism of Action of Regorafenib for Clinical Practice.
    Prager G
    Clin Adv Hematol Oncol; 2019 Aug; 17 Suppl 12(8):5-13. PubMed ID: 32720933
    [No Abstract]   [Full Text] [Related]  

  • 2. Current and Future Research Into the Mechanism of Action of Regorafenib.
    Yoshino T
    Clin Adv Hematol Oncol; 2019 Aug; 17 Suppl 12(8):14-16. PubMed ID: 32720934
    [No Abstract]   [Full Text] [Related]  

  • 3. Regorafenib (Stivarga) for metastatic colorectal cancer and GIST.
    Med Lett Drugs Ther; 2013 Apr; 55(1415):e36. PubMed ID: 23836345
    [No Abstract]   [Full Text] [Related]  

  • 4. Regorafenib in gastrointestinal stromal tumors.
    Sirohi B; Philip DS; Shrikhande SV
    Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib.
    Farooqi B; Simmons J; Hao Z
    J Gastrointest Cancer; 2015 Sep; 46(3):314-6. PubMed ID: 25859838
    [No Abstract]   [Full Text] [Related]  

  • 6. [A case of erythema multiforme induced by regorafenib therapy for metastatic colon cancer].
    Mii Y; Fukuoka E; Murata K; Otsubo D; Sawa H; Oka S; Iwatani Y; Kuroda D
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1841-3. PubMed ID: 25731348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib Treatment for Management of Colorectal Cancer: A Systematic Review and Meta-analysis of 6 Randomized Controlled Trials.
    Wang Y; Liu S; Liu S; Li X; Liu Q; Zou X; Zhu M; Jiang Y
    Am J Ther; 2018; 25(2):e276-e278. PubMed ID: 28938279
    [No Abstract]   [Full Text] [Related]  

  • 8. Regorafenib in the treatment of colorectal cancer.
    Majithia N; Grothey A
    Expert Opin Pharmacother; 2016; 17(1):137-45. PubMed ID: 26559195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Multikinase inhibitor regorafenib offers an efficient therapeutic alternative].
    Rev Med Suisse; 2014 May; 10(431):1108. PubMed ID: 24941678
    [No Abstract]   [Full Text] [Related]  

  • 10. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
    Shirley M; Keating GM
    Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Mechanism of Action of Regorafenib in Colorectal Cancer: A Guide for the Community Physician.
    Grothey A; Prager G; Yoshino T
    Clin Adv Hematol Oncol; 2019 Aug; 17 Suppl 12(8):1-19. PubMed ID: 32720931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic drug monitoring - 4th edition of the congress of pharmacology of anticancer drugs].
    Allard M; Rousseau B; Cardoso E; Bellesoeur A; Blanchet B
    Bull Cancer; 2017 Sep; 104(9):800-806. PubMed ID: 28756867
    [No Abstract]   [Full Text] [Related]  

  • 13. Regorafenib: A Review in Metastatic Colorectal Cancer.
    Dhillon S
    Drugs; 2018 Jul; 78(11):1133-1144. PubMed ID: 29943375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving role of regorafenib for the treatment of advanced cancers.
    Grothey A; Blay JY; Pavlakis N; Yoshino T; Bruix J
    Cancer Treat Rev; 2020 Jun; 86():101993. PubMed ID: 32199197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression-free survival with regorafenib in gastric cancer.
    Burki TK
    Lancet Oncol; 2016 Aug; 17(8):e323. PubMed ID: 27375105
    [No Abstract]   [Full Text] [Related]  

  • 16. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
    Callebout E; Ribeiro SM; Laurent S; De Man M; Ferdinande L; Claes KBM; Van der Meulen J; Geboes KP
    BMC Cancer; 2019 Jun; 19(1):567. PubMed ID: 31185985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib for the treatment of hepatocellular carcinoma.
    Tovoli F; Granito A; De Lorenzo S; Bolondi L
    Drugs Today (Barc); 2018 Jan; 54(1):5-13. PubMed ID: 29569657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors.
    Weekes C; Lockhart AC; Lee JJ; Sturm I; Cleton A; Huang F; Lenz HJ
    Int J Cancer; 2019 Nov; 145(9):2450-2458. PubMed ID: 30958892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling.
    Cai MH; Xu XG; Yan SL; Sun Z; Ying Y; Wang BK; Tu YX
    J Exp Clin Cancer Res; 2018 Jul; 37(1):151. PubMed ID: 30005681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.